India’s potential to become the pharmacy capital of the world, strangely, came to public knowledge after the US President Donald Trump threatened India to pursue retaliatory measures if the later didn’t export anti-malaria drug Hydroxychloroquine to the US for COVID-19 coronavirus treatment. Trump's Retaliation Threat over Hydroxychloroquine As a course of the conversation over the…Read More